Abstracts tagged "ACPA"

Abstract Number: 2450 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Abatacept Versus TNFi in Patients with RA Who Are CCP+ in the United States Corrona Registry
Leslie R Harrold¹, Heather J. Litman², SE Connolly³, E Alemao³, K Price³, S Kelly³, Sabrina Rebello⁴, W Hua² and Joel Kremer⁵, ¹University of Massachusetts, Worcester, MA, ²Corrona, Southborough, MA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Corrona, LLC, Southborough, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Anti-cyclic citrullinated peptide positivity (CCP+) is associated with a better response to abatacept than anti-CCP negativity in patients with RA1,2; however, there are no…
Abstract Number: 487 • 2017 ACR/ARHP Annual Meeting
ARE ANTI-Citrullinated Protein Antibody Levels Associated with Periodontal Disease in Rheumatoid Arthritis?
Jerián González Febles¹, Fernando Sánchez-Alonso², Jorge Luis Garnier Rodríguez³, Mariano Sanz Alonso¹, Federico Díaz-González⁴ and Beatriz Rodriguez Lozano^5,6, ¹Periodontology, Universidad Complutense de Madrid, Madrid, Spain, ²Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ³Odontology, Dental Clinic Garnier, S/C Tenerife, Spain, ⁴Servicio de Reumatología. Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵Rheumatology, Rheumatology Department. Hospital Universitario de Canarias, S/C TENERIFE, Spain, ⁶Rheumatology, Hospital de Canarias, S/C Tenerife, Spain
Background/Purpose: Positivity of anti-citrullinated peptides antibodies (ACPA) indicates severity in Rheumatoid Arthritis (RA). There is evidence for chronic periodontitis (PD) in RA autoimmune response by…
Abstract Number: 2791 • 2017 ACR/ARHP Annual Meeting
Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) and Marginal Jawbone Loss Predates the Onset of Rheumatoid Arthritis
Elin Kindstedt¹, Linda Johansson², Py Palmqvist³, Cecilia Koskinen Holm¹, Heidi Kokkonen⁴, Ingegerd Johansson³, Pernilla Lundberg³ and Solbritt Rantapaa-Dahlqvist⁵, ¹1Department of Odontology/Molecular Periodontology, Umeå University, Umeå, Sweden, ²Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ³Department of Odontology/Molecular Periodontology, Umeå University, Umeå, Sweden, ⁴Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ⁵Dept of Public Health and Clinical Medicine/Rheumatology, Umeå University, Sweden, Umeå, Sweden
Background/Purpose: Previous studies have shown a higher incidence of alveolar bone loss in patients with rheumatoid arthritis (RA) and that patients with periodontitis are at…
Abstract Number: 55 • 2016 ACR/ARHP Annual Meeting
Identification of Endogenous Autoantigens Bound to Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis: A Key Role for Citrulline Residues in Histone 4
Xiaobo Meng¹, Peyman Ezzati¹, Irene Smolik², Carol Hitchon³ and Hani El-Gabalawy⁴, ¹UNIVERSITY OF MANITOBA, WINNIPEG, MB, Canada, ²Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ³University of Manitoba, Winnipeg, MB, Canada, ⁴University of Manitoba Arthritis Center, Winnipeg, MB, Canada
Background/Purpose: Anti-Citrullinated Peptides Antibodies (ACPA) aid in rheumatoid arthritis (RA) diagnosis. The nature of autoantigens specifically bound to ACPA immune complex in vivoremains unclear. We…
Abstract Number: 571 • 2016 ACR/ARHP Annual Meeting
High Titer Rheumatoid Arthritis Antibodies Distinguish Between PAD2 and PAD4 Citrullinated Fibrinogen
Nathalie Blachere^1,2, Salina Parveen¹, Mayu Frank¹, Brian D. Dill¹, Henrik Molina¹ and Dana E. Orange^1,3,4, ¹The Rockefeller University, New York, NY, ²Howard Hughes Medical Institute, Chevy Chase, MD, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴The New York Genome Center, New York, NY
Background/Purpose: Most patients with rheumatoid arthritis (RA) harbor antibodies to citrullinated autoantigens, such as citrullinated fibrinogen. Two isoforms of peptidylarginine deiminase (PAD), PAD2 and PAD4,…
Abstract Number: 2035 • 2016 ACR/ARHP Annual Meeting
Dosage Contribution of a Non-Classical HLA Gene, HLA-Doa, to the Risk of Rheumatoid Arthritis
Yukinori Okada¹, Akari Suzuki², Katsunori Ikari³, Chikashi Terao⁴, Yuta Kochi², Koichiro Ohmura⁵, Koichiro Higasa⁵, Masato Akiyama², Kyoto Ashikawa², Masahiro Kanai², Jun Hirata¹, Naomasa Suita¹, Yik-Ying Teo⁶, Huji Xu⁷, Sang-Cheol Bae⁸, Yukihide Momozawa², koichi Matsuda⁹, Shigeki Momohara¹⁰, Atsuo Taniguchi¹⁰, Ryo Yamada⁵, Tsuneyo Mimori⁵, Michiaki Kubo², Matthew A. Brown¹¹, Soumya Raychaudhuri¹², Fumihiko Matsuda⁵, Hisashi Yamanaka¹⁰, Yoichiro Kamatani² and Kazuhiko Yamamoto⁹, ¹Osaka University, Osaka, Japan, ²Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ³Inst of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Departments of Genetics and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁶Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore, ⁷The Second Military Medical University, Shanghai, Japan, ⁸Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, The Republic of, ⁹The University of Tokyo, Tokyo, Japan, ¹⁰Tokyo Women's Medical University, Tokyo, Japan, ¹¹The University of Queensland Diamantina Institute, Brisbane, Australia, ¹²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Despite the progress in human leukocyte antigen (HLA) causal variant mapping, independent localization of major histocompatibility complex (MHC) risk from classical HLA genes is…
Abstract Number: 572 • 2016 ACR/ARHP Annual Meeting
Anti-Periodontal Bacteria Antibody Titers Are Inversely Correlated with ACPA in RA-Free Individuals with Periodontal Disease Compared to Community Controls
Emma Weeding¹, Londyn Robinson², Jeremy Sokolove³, Julie Marchesan⁴, Steven Offenbacher⁴, William H. Robinson³, Ryan Demmer⁵, Bryan Michalowicz⁶ and Jerry A. Molitor⁷, ¹Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ²University of Minnesota, Minneapolis, MN, ³Stanford University School of Medicine, Stanford, CA, ⁴Department of Periodontology, Dental School, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Epidemiology, Columbia University Mailman School of Public Health, New York, NY, ⁶Department of Developmental and Surgical Sciences, University of Minnesota, Minneapolis, MN, ⁷Rheumatic/Autoimmune Diseases, University of Minnesota, Minneapolis, MN
Background/Purpose: Rheumatoid arthritis (RA) and periodontal disease (PD) are comorbid conditions that share multiple underlying risk factors and pathophysiological features. A dysbiotic periodontal microbiome might…
Abstract Number: 2107 • 2016 ACR/ARHP Annual Meeting
Targeting Mir-155 in Rheumatoid Arthritis B Cells Reduces Antibody Production
Mariola Kurowska-Stolarska¹, Iain B McInnes², Stefano Alivernini³, Aziza Elmesmari⁴, Gianfranco Ferraccioli⁵, James Reilly² and David W. McCarey^6,7, ¹Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ⁴Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁵Division of Rheumatology - Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ⁶Glasgow Royal Infirmary, Glasgow, United Kingdom, ⁷Centre for Rheumatic Diseases, Centre for Rheumatic Diseases, Glasgow, United Kingdom
Background/Purpose: Better understanding of epigenetic regulatory mechanisms in RA pathogenesis will facilitate the development of new biomarkers or therapeutic strategies. MicroRNAs are post-transcriptional regulators that…
Abstract Number: 575 • 2016 ACR/ARHP Annual Meeting
Differences in Histological Scores and Histoclinical Correlations in ACPA- Versus ACPA+ Rheumatoid Arthritis Patients
Fadil Pirbuccus¹, Christine Galant¹, Adrien Nzeusseu Toukap², Frédéric A. Houssiau¹, Patrick Durez² and Bernard R. Lauwerys¹, ¹Pôle de pathologies rhumatismales inflammatoires et systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ²Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium
Background/Purpose: Differences in the pathogenesis of ACPA- versus ACPA+ rheumatoid arthritis are still poorly understood. In this study, we compared patterns of synovial changes in…
Abstract Number: 2111 • 2016 ACR/ARHP Annual Meeting
Generation and Characterization of Anti-Citrullinated Protein Antibody-Producing B-Cell Clones
Kristine Germar^1,2, Mark Kwakkenbos³, Sabrina Pollastro^1,2, Nathalie van Uden^1,2,4, Priscilla Kerkman⁵, Ellen I.H. van der Voort⁶, Evan Reed⁷, Karin Lundberg⁷, Niek de Vries^1,8, Lars Klareskog⁷, Hans U. Scherer⁵, René E.M. Toes⁵, Arjen Bakker³, Hergen Spits^3,9,10 and Dominique Baeten^1,2,10, ¹Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ³AIMM Therapeutics, Amsterdam, Netherlands, ⁴Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁸Clinical Immunology and Rheumatology F4-105, Amsterdam Rheumatology and immunology Center, location AMC, Amsterdam, Netherlands, ⁹Department of Cell Biology and Histology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ¹⁰These authors contributed equally to this work, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is the most frequent form of autoimmune arthritis with a prevalence of almost 1% worldwide. Anti-citrullinated protein antibodies (ACPA) are the…
Abstract Number: 582 • 2016 ACR/ARHP Annual Meeting
ACPA Induce Pathogenic Cytokines Expression in PBMC of ACPA+-RA Patients and Inhibition of Its Effect By Cit-ME a Synthetic Citrullinated Peptide
Smadar Gertel¹, Gidi Karmon², Eszter Szarka³, , Esther Houri-Levi⁴, Edna mozes⁵, Yehuda Shoenfeld⁴ and Howard Amital^6,7, ¹Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, ²Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel, ³Department of Immunology,, Eötvös Loránd University, Budapest,, Budapest, Hungary, ⁴Zabludowicz Center For Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel, Ramat-Gan, Israel, ⁵Department of Immunology,, The Weizmann Institute of Science, Rehovot, Israel., Rehovot, Israel, ⁶Department of Medicine B, Center for Autoimmune Diseases, Sheba Medical Center, Tel-hashomer, Israel, ⁷Department of Internal Medicine 'D', Sackler Faculty of Medicine, Tel-Aviv University, Kfar-Saba, Israel
ACPA induce pathogenic cytokines expression in PBMC of ACPA+-RA patients and inhibition of its effect by Cit-ME a synthetic citrullinated peptide.Smadar Gertel1, Gidi Karmon1, Eszter…
Abstract Number: 2496 • 2016 ACR/ARHP Annual Meeting
DMARD, Biologic and Small Molecule Drug Use Among ACPA Positive and ACPA Negative RA Patients in a Tertiary Referral Center
Richard Meehan¹, Eric Hoffman², David Muram³, Barbara Goldstein⁴, Jim Crooks⁵ and Pearlanne Zelarney⁶, ¹MEDICINE, National Jewish Health, Denver, CO, ²Medicine/Rheumjatology, National Jewish Health, denver, CO, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumatology, National Jewish Health, Denver, CO, ⁵Biostatistics, National Jewish Health, Denver, CO, ⁶Bioinformatics, National Jewish Health, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) can be divided into two major subsets based on the presence or absence of antibodies to citrullinated peptide antigens (ACPA). Some…
Abstract Number: 583 • 2016 ACR/ARHP Annual Meeting
Associations of Serum Anti-Citrullinated Proteins and Cytokines with Radiographic Scores in African-American Rheumatoid Arthritis Patients
Dongmei Sun¹, William H Robinson², Xiangqin Cui³, Vincent A. Laufer⁴, Maria I. Danila⁵, Richard J. Reynolds⁶, Chander Raman⁷, Stephanie Ledbetter⁸, Alexander Szalai⁹ and S. Louis Bridges Jr.⁹, ¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ³Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Rheumatology and Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷Medicine/Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸1825 University Blvd., University of Alabama at Birmingham, Birmingham, AL, ⁹Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Serum anti-citrullinated proteins (ACPA, including anti-CCP antibodies) and rheumatoid factor (RF) are critical diagnostic markers for RA, and are associated with more severe radiographic…
Abstract Number: 2612 • 2016 ACR/ARHP Annual Meeting
Sero-Positivity for Rheumatoid Factor Is an Independent Predictor for Achievement of Good EULAR Response at 24 Weeks in ACPA Positive Rheumatoid Arthritis Patients Treated with Abatacept: Results from Japanese Multicenter Registry
Nobunori Takahashi¹, Toshihisa Kojima¹, Shuji Asai¹ and Naoki Ishiguro², ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Nagoya University, Nagoya, Japan
Background/Purpose: Abatacept is a new class of biologic agent for the treatment of rheumatoid arthritis (RA) that inhibits T cell activation by binding to CD80/86.…
Abstract Number: 584 • 2016 ACR/ARHP Annual Meeting
Glycoprotein VI: A Potential Target for ACPA-Mediated Platelet Activation?
John Stack¹, Anne Madigan², Laura Helbert¹, Niamh Redmond¹, Eimear Dunne³, Dermot Kenny³ and Geraldine M. McCarthy², ¹Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ²Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ³Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland
Background/Purpose: Arterial thrombosis is a major cause of mortality in rheumatoid arthritis (RA),especially in anti-citrullinated protein antibody (ACPA)-positive patients Recent studies suggest that platelet activation…

« Previous Page
1
…
3
4
5
6
7
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].